IA
OTLK icon

IndexIQ Advisors’s Outlook Therapeutics OTLK Stock Holding History

IndexIQ Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,385
Closed -$255K – 1452
2021
Q4 		$255K Sell
9,385
-606
-6% -$21.6K 0.01% 989
2021
Q3 		$434K Buy
9,991
+1,001
+11% +$48.3K 0.01% 721
2021
Q2 		$448K Sell
8,990
-216
-2% -$10K 0.02% 549
2021
Q1 		$414K Buy
+9,206
New +$353K 0.01% 485

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VF
Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

IndexIQ Advisors's OTLK Position: Q1 2022 in Review

IndexIQ Advisors sold out of Outlook Therapeutics (OTLK) in Q1 2022, closing a stake of 9,385 shares — an estimated $255K sold.

IndexIQ Advisors first reported a position in OTLK in Q1 2021 and held it in 4 quarters. The position peaked at $448K in Q2 2021. 73 funds tracked by Wall St. Rank hold OTLK as of Q1 2022.

  • IndexIQ Advisors reported no remaining Outlook Therapeutics position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 9,385 Outlook Therapeutics shares in Q1 2022, an estimated $255K.
  • IndexIQ Advisors first reported a position in Outlook Therapeutics in Q1 2021 and held it in 4 quarters.
  • IndexIQ Advisors's Outlook Therapeutics position peaked at $448K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.